NDAORALTABLET, DELAYED RELEASE
Approved
May 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
DORYX (doxycycline hyclate) by AbbVie is tetracycline-class antimicrobial drug [ see ]. Approved for gonorrhea, chlamydia, syphilis and 1 more indications. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DORYX is a delayed-release oral tablet containing doxycycline hyclate, a tetracycline-class antimicrobial used to treat bacterial infections including gonorrhea, chlamydia, and syphilis, as well as acne vulgaris. It works by inhibiting bacterial protein synthesis, making it a broad-spectrum antibiotic with decades of clinical utility.
Peak8.6 years to LOE
Established product in peak commercial phase with stable acne and STI indications; brand team likely focused on market penetration and lifecycle extension rather than growth.
Mechanism of Action
tetracycline-class antimicrobial drug [ see ].
Indications (4)
Worked on DORYX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.